Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
Would you recommend hypofractionated PMRT with a positive deep margin?
How would you dose?
Answer from: Radiation Oncologist at Community Practice
I have used hypofractionated RT in this setting with final boost to area of positive margin equivalent to 60 Gy
Comments
Radiation Oncologist at Charlotte Hungerford Hospital
Thank you!
Radiation Oncologist at Bismarck Cancer Center
I agree, with a caveat - if the pathology report d...
Radiation Oncologist at Mallory Radiotherapy, PLLC
Dr. @Beriwal, what bolus regimen for the primary a...
Radiation Oncologist at Varian Medical Systems/Allegheny health network
If it’s a deep margin, then may avoid bolus ...
1396
1399
13525
13535
Sign in or Register to read more
5215
Related Questions
What hotspot and heterogeneity metrics do you utilize when delivering PMRT to a patient who has had breast reconstruction?
Do you recommend adjuvant RT to patients with non-ATM genetic mutations (e.g. BRCA, NF) who elect to have lumpectomy and are otherwise PRIME II/CALGB candidates for RT omission (i.e. low risk disease characteristics: strongly ER+, <1cm, grade 1-2, no LVI, widely negative margins, and committed to endocrine therapy)?
Is it reasonable to extrapolate the findings of RT Charm and Alliance to intact breast patients and offer hypofractionated RNI to all patients who are eligible for RNI?
When doing a tumor bed boost following whole breast irradiation, what do you typically use for CTV and PTV margin for photon and electron plans?
What are your top takeaways in Medical Oncology from SABCS 2024?
With the presentation of HypoG-01 phase III UNICANCER trial at ESMO 2024, should hypofractionated radiotherapy be the standard across the board for breast cancer?
Is 5fx APBI and no endocrine therapy a new standard of care for women over 70 years old with low-risk breast cancer given the interim analysis of the EUROPA trial?
How would you treat a patient with HER2 positive CNS only progression on fam-trastuzumab which had previously progressed on tucatinib/capecitabine/trastuzumab, and has failed both SRS and WBRT?
What is the earliest you would start postmastectomy radiation after adjuvant chemotherapy for a patient with breast cancer?
What volumes would you cover in a young patient with otherwise low risk breast cancer in whom the sentinel node failed to map and ALND was not performed?
Thank you!
I agree, with a caveat - if the pathology report d...
Dr. @Beriwal, what bolus regimen for the primary a...
If it’s a deep margin, then may avoid bolus ...